Tribunal upholds CMA’s decision to fine Lexon £1.2m
Company found to have broken competition law to drive up prices of antidepressant nortriptyline
Read More
Tag: Lexon
4 pharma companies accused of anti-competitive conduct
The CMA has accused Alissa, Lexon, King and Auden Mckenzie of engaging in anti-competitive conduct.
Read More
CMA accuses four pharmas of anticompetitive behaviour
Four pharma companies stand accused in the UK of colluding to artificially inflate the price of prescription-only, anti-nausea and dizziness drug prochlorperazine, costing the NHS millions of pounds and breaking competition law.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
